Michael Robinson, MD
Endocrinology, Diabetes & Metabolism · Inglewood, CANPI 1174634513
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $3,200 of the $3,933 with a category attached, or 81.4%. Pfizer accounts for 81.4% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2019 at $3,471 and has fallen 98.3% since, to $58 in 2024.
Across 18 payments — averaging $218.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$3K
- Lilly USA, LLC$266
- Davol Inc.$157
- Kestra Medical Technology Services, Inc.$145
- Insulet Corporation$125
- Amgen$40
Across 86 payments — averaging $2948.98 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$111K
- AstraZeneca$43K
- Astrazeneca UK Limited$36K
- Takeda Pharmaceuticals U.S.A., Inc.$24K
- Pfizer$23K
- AbbVie$11K
- plus $6K from 3 others
What the payments were for
- Speaking & faculty fees$3,20081%
- Travel & lodging$1574%
- Food & beverage$56714%
- Education$80%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 1 | $3,200 |
| Lilly USA, LLC | 8 | $266 |
| Davol Inc. | 1 | $157 |
| Kestra Medical Technology Services, Inc. | 2 | $145 |
| Insulet Corporation | 4 | $125 |
| Amgen | 2 | $40 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Assure WCD$103
How this compares
$3,933 in reported general payments places this provider in the 65th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 259 | $299,342 |
| TrulicityDulaglutide | 160 | $221,789 |
| JardianceEmpagliflozin | 159 | $186,476 |
| KerendiaFinerenone | 136 | $134,562 |
| FarxigaDapagliflozin Propanediol | 54 | $65,743 |
| MounjaroTirzepatide | 44 | $50,236 |
| JanuviaSitagliptin Phosphate | 48 | $44,280 |
| TradjentaLinagliptin | 42 | $33,070 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 24 | $18,275 |
| JanumetSitagliptin Phos/Metformin Hcl | 13 | $16,394 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 51 | $16,126 |
| Cinacalcet Hcl | 45 | $15,065 |
| Tresiba Flextouch U-100Insulin Degludec | 24 | $12,480 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $12,448 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 11 | $10,891 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Insulin Lispro, Humalog | $266 | $274,241232 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 952 endocrinology, diabetes & metabolism providers in California.
Other endocrinology, diabetes & metabolism in Inglewood
- Juan FriasSan Diego$1.4M
- Joselito CabaccanSan Jose$1.4M
- Daniel NadeauNewport Beach$1.2M
- Yehuda HandelsmanTarzana$1M
- Helen BaronRancho Mirage$958K
- Ken FujiokaSan Diego$747K
- Minou TranPico Rivera$663K
- James ChuMonterey$639K
- Anthony HeaneyLos Angeles$588K
- Daniel Einhornla Jolla$578K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.